Researchers studied whether these underlying mechanisms affect the prognostic role of Programmed Cell Death Ligand 1 (PD-L1). They retrospectively enrolled patients with EGFR mutant advanced stage NSCLC who received first-line EGFR-TKI between January 2017 and June 2019, the treatment efficacy of EGFR-TKI was assessed.
[Scientific Reports]